Trial Type: Head and Neck Cancer

LS-P-Poppy: First-in-class antibody-drug conjugate (ADC) targeting fibronectin (PYX-201) for solid tumors
Contact: Dr. Benedito Carneiro
This drug causes immune activation by blocking PTPN2/N1. The study drug is given alone and in combination with PD-1 inhibitors. Cohorts in kidney cancer, head and neck, and other solid tumors.
Contact: Dr. Benedito Carneiro
HEAT Trial
Bifunctional antibody against EGFR and TGF Beta, alone and in combination with pembrolizumab for Head and neck cancer, NSCLC and anal cancer and cutaneous squamous cell cancer
Contact: Dr. Ari Birnbaum